[Translation] A multicenter, prospective, randomized, double-blind, placebo-controlled phase 3 study to evaluate the safety and efficacy of ZS in patients with hyperkalemia
在基线时高钾血症经48小时开放期治疗后血钾达到正常的患者中,评价接受持续28天口服两种不同剂量(5和10g)ZS(qd)维持血钾正常的有效性(血清钾[S-K]在3.5~5.0 mmol/L范围内(包括3.5和5.0 mmol/L))。
[Translation] To evaluate the effectiveness of two different doses (5 and 10 g) of ZS (qd) given orally for 28 days to maintain normokalemia (serum potassium [S-K] within the range of 3.5 to 5.0 mmol/L, inclusive) in patients with hyperkalemia at baseline who achieved normokalemia after a 48-hour open-label period.